Skip to main content

Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren’s syndrome

Abstract

Objective

The main purpose of this study was to investigate the current situation of primary Sjögren’s syndrome (pSS) patients with interstitial lung disease (ILD) in China. The relationships between social demography, disease activity, psychological status, clinical variables, and ILD were analyzed. Besides that, the quality of life (QoL) in pSS with ILD was also analyzed.

Methods

In the cross-sectional study, 101 pSS patients participated in this study. Under the guidance of the researchers, the European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index (ESSDAI), EULAR Sjögren’s Syndrome Patient-Reported Index (ESSPRI), the Short-Form 36 health survey (SF-36), Hospital Anxiety and Depression Scale (HADS), Pittsburgh sleep quality index (PSQI), Summated Xerostomia Inventory (SXI), and other related questionnaires were completed. Independent sample t tests, Mann-Whitney U test, chi-square test, and correlational analysis were used.

Results

The data showed that 28 (30.1%) pSS people with ILD. The occurrence and development of ILD were associated with disease duration, fatigue, alanine aminotransferase (ALT), neutrophils, albumin, and use of hormone. The survey also found that the QoL of pSS-ILD was significantly lower than non-ILD, especially the score in the dimension of role physical function.

Conclusions

ILD was very common in pSS. ILD had a significant negative impact on the QoL of patients. Therefore, it is of great significance to strengthen the early intervention and drug treatment of pSS patients to prevent ILD and improve their QoL.

Key Points
This cross-sectional study finds that the incidence of ILD in patients with pSS is 30.1%.
The occurrence and development of ILD is associated with disease duration, fatigue, alanine aminotransferase (ALT), neutrophils, albumin, and use of hormone.
The study also finds that the QoL of pSS-ILD is significantly lower than in patients with non-ILD, especially the score in the dimension of role physical function.

This is a preview of subscription content, access via your institution.

References

  1. Nayar S, Campos J, Smith CG, Iannizzotto V, Gardner DH, Colafrancesco S, Pipi E, Kollert F, Hunter KJ, Brewer C, Buckley CD, Bowman SJ, Priori R, Valesini G, Juarez M, Fahy WA, Fisher BA, Payne A, Allen RA, Barone F (2019) Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjogren’s syndrome. Ann Rheum Dis 78(2):249–260

    CAS  Article  Google Scholar 

  2. Lin CY, Tseng CF, Liu JM et al (2019) Association between periodontal disease and subsequent Sjogren’s syndrome: a nationwide population-based cohort study. Int J Environ Res Public Health 16(5)

    CAS  Article  Google Scholar 

  3. Psianou K, Panagoulias I, Papanastasiou AD, de Lastic AL, Rodi M, Spantidea PI, Degn SE, Georgiou P, Mouzaki A (2018) Clinical and immunological parameters of Sjogren’s syndrome. Autoimmun Rev 17(10):1053–1064

    CAS  Article  Google Scholar 

  4. Cui Y, Li L, Xia L, Zhao Q, Chen S, Fu T, Ji J, Gu Z (2018) The impact of disease activity and psychological status on quality of life for Chinese patients with primary Sjogren’s syndrome. Patient Prefer Adherence 12:1513–1519

    Article  Google Scholar 

  5. Witte T (2018) Sjogren’s syndrome: early diagnosis and effective treatment[J]. Dtsch Med Wochenschr 143(24):1778–1782

    CAS  Article  Google Scholar 

  6. Tsigalou C, Stavropoulou E, Bezirtzoglou E (2018) Current insights in microbiome shifts in Sjogren’s syndrome and possible therapeutic interventions. Front Immunol 9:1106

    Article  Google Scholar 

  7. Price EJ, Baer AN 2019 How to treat Sjogren’s syndrome[J]. Rheumatology (Oxford)

  8. Zibrak JD, Price D (2014) Interstitial lung disease: raising the index of suspicion in primary care. NPJ Prim Care Respir Med 24:14054

    Article  Google Scholar 

  9. Dong X, Zhou J, Guo X, Li Y, Xu Y, Fu Q, Lu Y, Zheng Y (2018) A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjogren’s syndrome-related interstitial lung disease in a Chinese population. Clin Rheumatol 37(11):2981–2988

    Article  Google Scholar 

  10. Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Lévesque H, Marie I (2017) Interstitial lung disease in primary Sjogren’s syndrome. Autoimmun Rev 16(1):48–54

    CAS  Article  Google Scholar 

  11. Manfredi A, Sebastiani M, Cerri S, Cassone G, Bellini P, Casa GD, Luppi F, Ferri C (2017) Prevalence and characterization of non-sicca onset primary Sjogren syndrome with interstitial lung involvement. Clin Rheumatol 36(6):1261–1268

    Article  Google Scholar 

  12. Bajwah S, Yorke J (2017) Palliative care and interstitial lung disease. Curr Opin Support Palliat Care 11(3):141–146

    Article  Google Scholar 

  13. Chetta A, Marangio E, Olivieri D (2004) Pulmonary function testing in interstitial lung diseases. Respiration 71(3):209–213

    Article  Google Scholar 

  14. Kishaba T, Mcgill R, Nei Y et al (2018) Clinical characteristics of dermatomyosits/polymyositis associated interstitial lung disease according to the autoantibody. J Med Invest 65(3.4):251–257

    Article  Google Scholar 

  15. Cottin V, Hirani NA, Hotchkin DL et al (2018) Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. Eur Respir Rev 27(150)

    Article  Google Scholar 

  16. Cottin V, Wollin L, Fischer A et al (2019) Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir Rev 28:–151

    Article  Google Scholar 

  17. Kampolis CF, Fragkioudaki S, Mavragani CP et al (2018) Prevalence and spectrum of symptomatic pulmonary involvement in primary Sjogren’s syndrome. Clin Exp Rheumatol 36 Suppl 112(3):94–101

    PubMed  Google Scholar 

  18. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X (2017) the International Sjögren’s Syndrome Criteria Working Group 2016 American College of Rheumatology/European league against rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol 69(1):35–45

    Article  Google Scholar 

  19. Li L, Gao S, Fu Q, Liu R, Zhang Y, Dong X, Li Y, Li M, Zheng Y (2019) A preliminary study of lung abnormalities on HRCT in patients of rheumatoid arthritis-associated interstitial lung disease with progressive fibrosis. Clin Rheumatol

  20. Nocturne G 2019 [Sjogren’s syndrome update: clinical and therapeutic aspects][J]. Rev Med Interne

  21. Rosas J, Sanchez-Piedra C, Fernandez-Castro M et al (2019) ESSDAI activity index of the SJOGRENSER cohort: analysis and comparison with other European cohorts. Rheumatol Int 39(6):991–999

    Article  Google Scholar 

  22. Li Z, Fu T, Li L, Cui Y, Dong C, Li J, Gu Z (2018) Prevalence, severity, and predictors of dry eye and dry mouth in Chinese patients with primary Sjogren syndrome. Clin Rheumatol 37(11):2971–2979

    Article  Google Scholar 

  23. He SL, Wang JH, Li M (2013) Validation of the Chinese version of the summated xerostomia inventory (SXI). Qual Life Res 22(10):2843–2847

    Article  Google Scholar 

  24. Bollmeier SG, Seaton TL, Prosser TR et al (2003) Assessment of symptom burden and adherence to respiratory medications in individuals self-reporting a diagnosis of COPD within a community pharmacy setting. J Am Pharm Assoc 2019

  25. Cui Y, Xia L, Li L et al (2018) Anxiety and depression in primary Sjogren’s syndrome: a cross-sectional study. BMC Psychiatry 18(1):131

    Article  Google Scholar 

  26. Miyamoto ST, Valim V, Fisher BA (2019) Health-related quality of life and costs in Sjogren’s syndrome. Rheumatology (Oxford)

  27. Priori R, Minniti A, Antonazzo B et al (2016) Sleep quality in patients with primary Sjogren’s syndrome. Clin Exp Rheumatol 34(3):373–379

    PubMed  Google Scholar 

  28. Haldorsen K, Bjelland I, Bolstad AI et al (2011) A five-year prospective study of fatigue in primary Sjogren’s syndrome. Arthritis Res Ther 13(5):R167

    CAS  Article  Google Scholar 

  29. Chen MH, Chen CK, Chou HP et al (2016) Rituximab therapy in primary Sjogren’s syndrome with interstitial lung disease: a retrospective cohort study. Clin Exp Rheumatol 34(6):1077–1084

    PubMed  Google Scholar 

  30. Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality--a retrospective study based on registry data. Rheumatology (Oxford) 52(1):173–179

    Article  Google Scholar 

  31. Wang Y, Hou Z, Qiu M, Ye Q (2018) Risk factors for primary Sjogren syndrome-associated interstitial lung disease. J Thorac Dis 10(4):2108–2117

    Article  Google Scholar 

  32. Kakugawa T, Sakamoto N, Ishimoto H, Shimizu T, Nakamura H, Nawata A, Ito C, Sato S, Hanaka T, Oda K, Kido T, Miyamura T, Nakashima S, Aoki T, Nakamichi S, Obase Y, Saito K, Yatera K, Ishimatsu Y, Nakayama T, Korogi Y, Kawakami A, Tanaka Y, Mukae H (2018) Lymphocytic focus score is positively related to airway and interstitial lung diseases in primary Sjogren’s syndrome. Respir Med 137:95–102

    Article  Google Scholar 

  33. Gao H, Zhang XW, He J, Zhang J, An Y, Sun Y, Jia RL, Li SG, Zhang LJ, Li ZG (2018) Prevalence, risk factors, and prognosis of interstitial lung disease in a large cohort of Chinese primary Sjogren syndrome patients: a case-control study. Medicine (Baltimore) 97(24):e11003

    Article  Google Scholar 

  34. Yazisiz V, Arslan G, Ozbudak IH, Turker S, Erbasan F, Avci AB, Ozbudak O, Terzioglu E (2010) Lung involvement in patients with primary Sjogren’s syndrome: what are the predictors? Rheumatol Int 30(10):1317–1324

    Article  Google Scholar 

  35. O’neill ID, Scully C (2013) Biologics in oral medicine: Sjogren syndrome. Oral Dis 19(2):121–127

    Article  Google Scholar 

  36. Wollin L, Distler JHW, Redente EF, Riches DWH, Stowasser S, Schlenker-Herceg R, Maher TM, Kolb M (2019) Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J:1900161

    Article  Google Scholar 

  37. Hartung W, Maier J, Pfeifer M et al (2012) Effective treatment of rheumatoid arthritis-associated interstitial lung disease by B-cell targeted therapy with rituximab. Case Reports Immunol 2012:272303

    Article  Google Scholar 

  38. Natalini JG, Swigris JJ, Morisset J, Elicker BM, Jones KD, Fischer A, Collard HR, Lee JS (2017) Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respir Med 127:1–6

    Article  Google Scholar 

Download references

Acknowledgments

The authors want to thank Wei Zhou, Jiaxin Guo, Mei He Ping Li, and Jianlin Gao for their assistance with this paper.

Funding

This work was supported by the Postgraduate Research and Practice Innovation Program of Jiangsu Province (grant number KYCX19-2071), National Natural Science Foundation of China (grant number 81671616 and 81871278), Science and technology Project of Jiangsu Province (grant number BE2018671), and Research Center of Gerontology and Longevity, Affiliated Hospital of Nantong University, Nantong (grant number HS2018004).

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Zhifeng Gu or Chen Dong.

Ethics declarations

The Ethics Committee of the Affiliated Hospital of Nantong University approved this study (ethics approval number: 2017-K003).

All participants obtained informed consent in the study.

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zhao, R., Wang, Y., Zhou, W. et al. Associated factors with interstitial lung disease and health-related quality of life in Chinese patients with primary Sjögren’s syndrome. Clin Rheumatol 39, 483–489 (2020). https://doi.org/10.1007/s10067-019-04753-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-019-04753-5

Keywords

  • China
  • Interstitial lung disease
  • Primary Sjögren’s syndrome
  • Quality of life